Clinical trials: Chronic Heart Failure
Heart Failure, Growth Hormone Deficiency
Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
The aim of this study is to investigate the potential benefits of the correction of growth hormone (GH) deficiency with GH replacement therapy in patients with chronic heart failure due to left ventricular systolic dysfunction.
- Conditions
- Heart Failure, Growth Hormone Deficiency, Ischemic Heart Disease
- Trial name
- NCT00591760
- Testing
- Somatotropin
- Volunteers
- 56 people
- Sponsor
- Federico II University
Heart Failure, Congestive
Effect of Chronic Changes in Heart Rate on Congestive Heart Failure
This will be a double blind randomized crossover study of patients with congestive heart failure and a heart rate dependent upon a permanent pacemaker.
- Trial name
- NCT00389649
- Testing
- heart rate setting
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, Baltimore
Chronic Heart Failure
Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology
Targeted population: Patients with heart failure causing hospitalization during the last twelve months. Hypothesis: The number of all cause deaths and hospitalizations will be smaller for the Telecardiology group than for the…
- Trial name
- OSICAT (NCT02068118)
- Testing
- Telecardiology program
- Where
- 38 sites in France, Martinique
- Volunteers
- 990 people
- Sponsor
- CDM e-Health
Asthma, Chronic Obstructive Pulmonary Disease
Usability and Acceptability Study of the P-STEP Mobile Application
Assess the usability and acceptance of the P-STEP app, through allowing participants with specific chronic conditions to pilot the app for 12-weeks.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease, Coronary Heart Disease
- Trial name
- NCT05830318
- Testing
- P-STEP Mobile Application
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- University of Leicester
Chronic Obstructive Pulmonary Disease, Heart Failure
Adjusting to Chronic Conditions Using Education, Support, and Skills
The current study seeks to test the effectiveness of a talk-therapy intervention designed to better meet the needs of chronically ill Veterans.
- Conditions
- Chronic Obstructive Pulmonary Disease, Heart Failure, Anxiety, Depression
- Trial name
- ACCESS (NCT01149772)
- Testing
- ACCESS
- Where
- 2 sites in United States
- Volunteers
- 302 people
- Sponsor
- VA Office of Research and Development
NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C
The objective of this investigation is to evaluate the safety and effectiveness of the OPTIMIZER® System in subjects with medically refractory moderate-to-severe heart failure.
- Trial name
- FIX-HF-5C (NCT01381172)
- Testing
- Optimizer System, No intervention: Optimal medical therapy
- Where
- 42 sites in United States, Czechia and 1 more
- Volunteers
- 160 people
- Sponsor
- Impulse Dynamics
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
The goal of this research agenda is to improve the quality of end-of-life care by explicitly identifying values that will guide the decision-making process, with a particular emphasis on the role of ethnic, racial and cultural…
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma
- Trial name
- Aim3 (NCT00122135)
- Testing
- Values Inventory (VI)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Cardiac Resynchronization Therapy, Chronic Heart Failure
Exercise Training Following Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure
Cardiac resynchronization therapy(CRT) is recommended to reduce mortality and morbidity in chronic heart failure(CHF) patients New York Heart Association(NYHA) class III-IV who are symptomatic despite optimal medical therapy…
- Trial name
- NCT02413151
- Testing
- Exercise training program, Cardiac resynchronization therapy (CRT)
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- University of Lisbon
Diabetes Mellitus, Type 2
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
The primary objective of this exploratory meta-analysis is to evaluate the frequencies, incidence rates, and hazard ratios of lower-limb amputation (LLA) events (primary outcome) and of adverse events related to amputation…
- Trial name
- NCT04937816
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 16,746 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease, Coronary Artery Disease
Coronary Artery Disease Screening in Kidney Transplant Candidates
Kidney transplant candidates are at very high risk for coronary artery disease (CAD). The optimal strategy to monitor and maintain the cardiac fitness of patients awaiting kidney transplantation is unknown.
- Trial name
- CADScreening (NCT02082483)
- Testing
- Selective Screening
- Where
- 6 sites in Canada
- Volunteers
- 144 people
- Sponsor
- University of British Columbia
Chronic Heart Failure
Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure
The purpose of this study is to determine if oral iron (Fe) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 (oxygen uptake) by CPET (Cardiopulmonary Exercise Testing)…
- Trial name
- IRONOUT (NCT02188784)
- Testing
- Polysaccharide Iron Complex 150 mg
- Where
- 17 sites in United States
- Volunteers
- 225 people
- Sponsor
- Adrian Hernandez
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Early Warning System
The study will begin in 2013 whereby patients having an early warning system (EWS) alert will be randomized to be seen by the rapid response team (RRT) for triage versus usual care.
- Conditions
- Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cancer, Diabetes Mellitus
- Trial name
- NCT01741480
- Testing
- Early warning system monitoring., routine care
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Washington University School of Medicine
Hepatitis C, Chronic, Heart Failure
Hepatitis C Virus(HCV) Heart and Lung Study
This is a multicenter study in Hepatitis C Virus (HCV) infected adult patients who also have advanced cardiac disease or advanced lung disease.
- Conditions
- Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive, Lung Diseases, Interstitial
- Trial name
- NCT02858180
- Testing
- Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Duke University
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic…
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure
- Trial name
- COSMIC-HF (NCT01786512)
- Testing
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Omecamtiv Mecarbil Swellable Core Technology F2
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 544 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Hemodialysis (ESRD)
Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD
This study is a pilot study designed to compare the safety and cardiovascular effects of 26 weeks of combination hydralazine/isorsorbide dinitrate therapy with placebo therapy in patients receiving chronic hemodialysis.
- Trial name
- HIDE (NCT02228408)
- Testing
- Hydralazine/Isorsorbide Dinitrate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals